Once-Daily Administration of Intranasal Corticosteroids for Allergic Rhinitis: A Comparative Review of Efficacy, Safety, Patient Preference, and Cost

Herman, Howard

doi:10.2500/ajr.2007.21.2896

Cited by 58 publications

(60 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corticosteroids Intranasal corticosteroids are the most effective agents for the treatment of seasonal allergic rhinitis [42][43][44]. Symptoms, including nasal congestion, are better relieved by intranasal corticosteroids than by placebo [19,33].…”

Section: Pharmacotherapymentioning

confidence: 99%

Seasonal Allergic Rhinitis

Leung

Hon²

2008

IAD

View full text Add to dashboard Cite

Seasonal allergic rhinitis is characterized by seasonal rhinorrhea, nasal congestion/stuffiness, nasal and ocular pruritus, and paroxysmal sneezing. Symptomatic relief and improved quality of life can be achieved in the majority of patients by using pharmacotherapy appropriately. Mild cases can be managed with either an oral antihistamine or a nasal corticosteroid alone. More severe cases may require a nasal corticosteroid in combination with various agents. Immunotherapy is reserved for a selected group of patients. While all other interventions provide symptomatic relief, specific immunotherapy may have long-term effects. This review article also discuss recent patents related to the field.

show abstract

Section: Pharmacotherapymentioning

confidence: 99%

Seasonal Allergic Rhinitis

Leung

Hon²

2008

IAD

View full text Add to dashboard Cite

show abstract

“…[1] Treatment of allergic rhinitis has been revolutionized by the introduction of topical nasal steroid sprays, which are the commonest prescription from otolaryngology departments. The regular use of nasal steroid sprays reduces nasal obstruction, rhinorrhea and overall nasal symptom scores.…”

Section: Introductionmentioning

confidence: 99%

Determination of triamcinolone in human plasma by a sensitive HPLC–ESI‐MS/MS method: application for a pharmacokinetic study using nasal spray formulation

César¹,

Byrro²,

Cardoso³

et al. 2011

J. Mass Spectrom.

View full text Add to dashboard Cite

A liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) method for the quantitation of triamcinolone in human plasma after nasal spray application was developed and validated. Betamethasone was used as internal standard (IS). The analytes were extracted by a liquid-liquid procedure and separated on a Zorbax Eclipse XDB C(18) column with a mobile phase composed of 2 mM aqueous ammonium acetate pH 3.2 and acetonitrile (55:45). Selected reaction monitoring was performed using the transitions m/z 435 → 415 and m/z 393 → 373 to quantify triamcinolone acetonide and betamethasone, respectively. Calibration curve was constructed over the range of 20-2000 pg/ml for triamcinolone acetonide. The lower limit of quantitation was 20 pg/ml. The mean RSD values were 4.6% and 5.7% for the intra-run and inter-run precision, respectively. The mean accuracy value was 98.5% and a recovery rate corresponding to 97.5% was achieved. No matrix effect was detected in the samples. The validated method was successfully applied to determine the plasma concentrations of triamcinolone acetonide in healthy volunteers, in a pharmacokinetic study with nasal spray formulation.

show abstract

“…Double blind, placebo-controlled studies on budesonide (Creticos et al 1998;Andersson et al 2000;Day et al 2000Day et al , 2001, fl uticasone propionate (Nathan et al 1991;Dolovich et al 1994;LaForce et al 1994Foresi et al 1996, mometasone fuorate (Bronsky et al 1997;Berkowitz et al 1999a, b;Gawchik et al 2003), and triamcinolone acetonide (Munk et al 1996;Settipane et al 2002) have shown that once-daily administration of these ICS are well tolerated and more effective than placebo in the treatment of seasonal AR (SAR) and perennial AR (PAR) (Herman 2007).…”

Section: Ciclesonidementioning

confidence: 99%

“…Factors that will potentially improve adherence to treatment and differentiate the inhaled corticosteroids are dosing, regimen, patient preference and costeffectiveness (Dupclay and Doyle 2002;Herman 2007).…”

Section: From Available Glucocorticosteroids To Ciclesonidementioning

confidence: 99%

See 1 more Smart Citation

New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

Braido

Lagasio²,

Piroddi³

et al. 2008

TCRM

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a chronic infl ammatory respiratory disease affecting 5%-50% of the worldwide population and its prevalence is increasing (Herman 2007). In addition, AR is associated with asthma and other co-morbidities such as conjunctivitis and sinusitis. The main symptoms are nasal congestion, rhinorrea, sneezing, itching, and post-nasal drainage induced after allergen exposure by an IgE-mediated infl ammation of the membranes lining the nose. AR is not a life-threatening disease, but it has been shown to have a signifi cant impact on quality of life. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines propose a classifi cation of AR in intermittent and persistent, each graded as mild or moderate-severe, and provide a stepwise approach to the treatment. Inhaled steroids and antihistamine are the main tools in AR therapy but more safe and effective drugs are, however, needed. Inhaled steroid ciclesonide appears to be safe and effective.

show abstract

Once-Daily Administration of Intranasal Corticosteroids for Allergic Rhinitis: A Comparative Review of Efficacy, Safety, Patient Preference, and Cost

Abstract: BANS, FPNS, MFNS, and TANS have similar efficacy and safety profiles. Differences in sensory attributes, documented safety during pregnancy, and cost may contribute to better patient acceptance of one INS versus another and promote better adherence to therapy.

Cited by 58 publications

References 61 publications

Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

Determination of triamcinolone in human plasma by a sensitive HPLC–ESI‐MS/MS method: application for a pharmacokinetic study using nasal spray formulation

New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

Contact Info

Product

Resources

About